Scientists have found that the technique can distinguish between two different subtypes of ovarian cancer, to reveal their sensitivities to treatment. They used it to look at patient-derived cell ...
Indeed, there is a need for molecular tools that are based on robust biomarkers specific to clinical outcomes of ovarian cancer subtypes, and for assay platforms that can be easily adapted for ...